drugset / Trial / NCT00664287

Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

NCT00664287

Phase 3 Withdrawn Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to test the effect of MK0524A (niacin (+) laropiprant) on lowering bad cholesterol and raising good cholesterol.

Timeline

Start
2008-09
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Niacin Small molecule 2 g
Subject laropiprant Small molecule 40 mg

Indications